Navigation Links
InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
Date:9/13/2010

InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed the Phase 3 CAPACITY program in patients with IPF. A Marketing Authorization Application (MAA) for pirfenidone is under review by the European Medicines Agency (EMA). The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 and ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company has submitted in support of its New Drug Application (NDA) and MAA filings. Furthermore, while the Pulmonary-Allergy Drugs Advisory Commi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Release Second Quarter Financial Results on July 27
2. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
3. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
4. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
5. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
6. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
7. InterMune to Present at Deutsche Bank Biotech Confab
8. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
9. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
10. InterMune to Present at JMP Securities Conference
11. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... the second half of this yearBERLIN and TARRYTOWN, N.Y., ... Inc. (Nasdaq: REGN ) today announced that ... VEGF Trap-Eye, an investigational agent for the treatment of ... (CRVO). The companies plan to initiate a Phase 3 ...
... Investing in New Product Presentations for PatientsSAN DIEGO and ... AMLN ) and Eli Lilly and Company (NYSE: ... have agreed in principle to the terms of a ... device. Separately, the companies announced that they have initiated ...
Cached Medicine Technology:Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 2Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 3Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 4Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 6Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 7
(Date:7/12/2014)... Praeclarus Press is excited to ... new resource for women in need of lactation support. ... away from their children. Today’s mothers receive very clear ... but often feel unsupported when it comes to balancing ... evidence-based insights, and written by Nancy Mohrbacher, an international ...
(Date:7/12/2014)... Angeles, CA (PRWEB) July 12, 2014 ... buyer power score of 4.1 out of 5. ... market that have been underpinning buyer negotiation power ... IBISWorld procurement analyst Anna Son, “during the period, ... with rising costs associated with new product development, ...
(Date:7/12/2014)... July 12, 2014 Ladies, it doesn't matter ... there. Those who are looking for an affordable gown can ... special occasion dresses) to get their dream items. Recently, the ... tea length gowns . Along with that, it is also ... enjoy the special offer; the deadline of this promotion is ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
(Date:7/11/2014)... 11, 2014 As transvaginal mesh ... Johnson & Johnson’s Ethicon Inc. unit continue to ... that the Texas Attorney General’s Office has acknowledged ... surgical mesh products used to treat pelvic organ ... report from kens5.com, the probe began nearly two ...
Breaking Medicine News(10 mins):Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... with chronic obstructive pulmonary disease (COPD) who are hospitalized ... decreased mortality when compared to those who are not ... almost 16,000 COPD patients admitted to VA hospitals. ... edition of the American Thoracic Society,s American Journal ...
... FRIDAY, April 15 (HealthDay News) -- Is estrogen breast cancer,s ... Journal of the American Medical Association , which analyzed data ... when it found a reduced risk of breast cancer in ... This seemed to contradict years of cautions that estrogen therapy ...
... , FRIDAY, April 15 (HealthDay News) -- Losing weight can ... obese, but not all diet plans are effective in lowering ... against cancer are those that encourage long-term changes in eating ... food groups, explained Daxaben Amin, a senior clinical dietitian in ...
... New York, N.Y. (April 15, 2011) A comprehensive ... Autism Tissue Program (ATP), a postmortem brain tissue donation ... autism also had epilepsy, and co-morbidity data from the ... than expected rate of mortality in individuals with both ...
... HealthDay Reporter , THURSDAY, April 14 (HealthDay News) -- Seniors ... with their neighbors stand a much better chance of surviving ... each increase in what researchers call neighborhood "cohesion," such as ... on a neighbor for help, the odds of survival after ...
... elective surgery reduces potentially serious kidney complications, according to ... Journal of the American Society Nephrology (JASN). ... surgeries are performed around the world. Unfortunately, many patients ... surgery, often due to decreased blood flow to the ...
Cached Medicine News:Health News:Large study finds ICS therapy reduces pneumonia mortality 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 3Health News:A Good Diet Includes Many Cancer-Fighting Foods: Expert 2Health News:Mortality rate is increased in persons with autism who also have epilepsy 2Health News:Close-Knit Neighborhoods Raise Chances of Stroke Survival 2Health News:Statins may protect against kidney complications following elective surgery 2
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Straight double action bone cutting rongeur....
Beuse Zygomatic Arch Awl with slightly curved tip....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: